Hot topics in biomanufacturing & tech parks

The production of biopharmaceuticals as well as microbial, cell-free or cell-based industrial production requires interdisciplinary teams, service providers and, above all, space for R&D, scaling and production. While the pandemic mainly triggered the expansion of R&D centres and production sites for pharmaceuticals, vaccines and diagnostics, other sectors such as chemicals, food or energy are now pushing in the wake of the defossilisation of industrial production. The call from Europe’s incubators for life sciences start-ups is increasingly audible for more laboratory, demonstration and production space. The industry is gearing up for expansion, and property developers, plant builders and licensing authorities have their work cut out for them.

Make your cluster, incubator, production site visible across Europe

Whether biopharmaceuticals, plastic defossilisation or novel foods from CO2, insects, cells or precision fermentation, SMEs need support in developing, financing, scaling up and producing their biotech products. European Biotechnology goes out to decision makers throughout the entire European Life Science sectors. Take advantage of the journal’s highly relevant readership and grab this opportunity to target your audience!

Topics to be covered

Europe’s cluster locations are bursting at the seams in the face of exploding demand for new therapy formats such as mRNAs, cell & gene therapies, molecular machines or conjugates, vegan protein or enzymatically produced defossilised chemical products and energy. More space and additional expertise must be developed and financed. Make your industrial, pharmaceutical or agribiotechnology location visible to professionals and companies looking to relocate. The first Europe-wide special Production Sites & Tech Parks offers your company or cluster organisation an editorial environment in which you can present your expertise, in an author article, advertorial, interview and much more. Our experts will be happy to advise you.